DOI: https://doi.org/10.22263/2312-4156.2018.1.59
Talako T.M., Soroka N.F.
Correction of vitamin D deficiency in patients with suspected and verified antiphospholipid syndrome
Belarusian State Medical University, Minsk, Republic of Belarus
Vestnik VGMU. 2018;17(1):59-67.
Abstract.
Objectives. To study the effect of vitamin D supplementation on the content of total vitamin D and the level of antiphospholipid antibodies (APLA) in the blood of APLA-positive patients with probable and verified antiphospholipid syndrome (APS) with initial hypovitaminosis D.
Material and methods. 58 patients with APS were examined. Patients with diagnosed vitamin D hypovitaminosis were selected for further observation and investigation of the effect of cholecalciferol on the level of APLA: 21 patients with verified APS and 9 patients with probable APS. The blood levels of antibodies to cardiolipin and β2-glycoprotein I (anti-β2-GP I) were determined by ELISA test, the content of total vitamin D (25(OH)D) – by chemiluminescence method.
Results. It was found that the addition of cholecalciferol at a dose of 500-1500 IU/day during 6 months leads to a significant increase in the mean level of 25(OH)D in the blood: before treatment – 15,27 (12,56-17,45) ng/ml, after treatment – 28,60 (22,46-36,10) ng/ml (Z=4,66, p=0,001) and an increase in the proportion of patients with the level of 25(OH)D ≥ 20 ng/ml (χ2McN=16,41, p=0,001). After vitamin D supplementation a significant reduction in the level of anti-β2-GP I antibodies of IgG class was revealed (Z=2,39; p=0,017).
Conclusions. The administration of cholecalciferol in addition to the traditional treatment of APS leads to an increase in the level of 25(OH)D in the blood and a decrease in the level of anti-β2-GP I antibodies of IgG class and is pathogenetically justified in APLA-positive patients.
Key words: cholecalciferol, antiphospholipid syndrome, antibodies to β2-glycoprotein I, vitamin D.
References
1. Egshatyan LV, Dudinskaya EN, Tkacheva ON, Kashtanova DA. The role of vitamin D in the pathogenesis of chronic non-infectious diseases. Osteoporoz i osteopatii. 2014;1:27-30. (In Russ.)
2. Pike JW, Meyer MB. Fundamentals of vitamin D hormone-regulated gene expression. J Steroid Biochem Mol Biol. 2014 Oct;144(Pt A):5-11. doi: http://dx.doi.org/10.1016/j.jsbmb.2013.11.004
3. Maruotti N, Cantatore FP. Vitamin D and the immune system. J Rheumatol. 2010 Mar;37(3):491-5. doi: http://dx.doi.org/10.3899/jrheum.090797
4. Palmer MT, Lee YK, Maynard CL, Oliver JR, Bikle DD, Jetten AM, et al. Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the development of effector CD4 T cells. J Biol Chem. 2011 Jan;286(2):997-1004. doi: http://dx.doi.org/10.1074/jbc.M110.163790
5. Van Belle TL, Vanherwegen AS, Feyaerts D, De Clercq P, Verstuyf A, Korf H, et al. 1,25-dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One. 2014 Oct;9(10):e109194. doi: http://dx.doi.org/10.1371/journal.pone.0109194
6. Dal Ben ER, do Prado CH, Baptista TS, Bauer ME, Staub HL. Decreased levels of circulating CD4+25+Foxp3+ regulatory cells in patients with primary antiphospholipid syndrome. J Clin Immunol. 2013 May;33(4):876-9. doi: http://dx.doi.org/10.1007/s10875-012-9857-y
7. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev. 2012 Dec;12(2):127-36. doi: http://dx.doi.org/10.1016/j.autrev.2012.07.007
8. Norman PE, Powell JT. Vitamin D and Cardiovascular Disease. Circ Res. 2014 Jan;114(2):379-93. doi: http://dx.doi.org/10.1161/CIRCRESAHA.113.301241
9. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011 Jan;70(1):145-50. doi: http://dx.doi.org/10.1136/ard.2010.134817
10. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: http://dx.doi.org/10.1210/jc.2011-0385
11. Ruiz-Arruza I, Ugarte A, Cabezas-Rodrigues I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014 Aug;53(8):1470-6. doi: http://dx.doi.org/10.1093/rheumatology/keu148
12. Martinuzzo ME, Barrera LH, D’adamo MA, Otaso JC, Gimenez MI, Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol. 2014 Apr;36(2):144-50. doi: http://dx.doi.org/10.1111/ijlh.12138
13. Soroka NF, Talako TM. A method of reduction the level of immunoglobulins class G to β2-glycoprotein Ι in patients with antiphospholipid syndrome: pat 21345 Resp Belarus': MPK A 61K 31/593, A 61P 7/02 № a20140561; zaiavl 27.10.14; opubl 30.10.17, Ofits Biul Izobreteniia Poleznye modeli Promyshlennye obraztsy Topologii integral'nykh mikroskhem № 5 (118). Р. 75. (In Russ.)
14. Dankers W, Colin EM, van Hamburg JP, Lubberts E. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. Front Immunol. 2017 Jan;7:697. doi: http://dx.doi.org/10.3389/fimmu.2016.00697
15. Karimzadeh H, Shirzadi M, Karimfar M. The effect of Vitamin D supplementation in disease activity of systemic lupus erythematosus patients with Vitamin D deficiency: A randomized clinical trial. J Res Med Sci. 2017 Jan;22:4. doi: http://dx.doi.org/10.4103/1735-1995.199089
16. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol. 2010 Mar;40(3):265-72. doi: http://dx.doi.org/10.3899/jrheum.111594
Information about authors:
Talako T.M. – postgraduate of the Chair of Internal Medicine No.2, Belarusian State Medical University;
Soroka N.F. – Doctor of Medical Sciences, professor, head of the Chair of Internal Medicine No.2, Belarusian State Medical University.
Correspondence address: Republic of Belarus, 220116, Minsk, 83 Dzerzhinskogo ave., Belarusian State Medical University, Chair of Internal Medicine No.2. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Nikolay F. Soroka.
